新基制药(CELG)

张小丰2017-07-14 21:39

$新基制药(CELG)$ 如果我现在突然来一大笔美元。目测还是会买入新基查看全文

百济神州的基本面发生了天翻地覆的变化

张小丰2017-07-06 17:13

今天大新闻来了。 新基和百济深度合作。新基不愧是医药界的VC，而且给小弟的合作方案从来都很慷慨大方。
1：新基获得百济PD1对实体瘤的全球权益，除了中国还有血液瘤归属百济。还有百济内部产品的组合疗法也属于百济。PD1的全球关键性实验将于2018年开展。
2：新基首付2.63亿美元，里程碑...查看全文

an小安2017-07-06 10:43

$百济神州(BGNE)$ $新基制药(CELG)$ 新基公司和百济神州在免疫肿瘤领域达成全球战略合作 共同在实体肿瘤领域推进PD-1抑制剂项目 网页链接查看全文

二的有理有据2017-06-17 09:36

$新基制药(CELG)$ 新的估值150 …Celgene outperforms after upgrade
网页链接查看全文

自由ziyi2017-05-11 16:51

$新基制药(CELG)$ 盘前怎么跌了那么多？有什么情况查看全文

Yucheng_Chen2017-05-09 02:46

网页链接
难道这一个事情就可以让$新基制药(CELG)$ 跌3%……查看全文

张小丰2017-04-14 12:30

$新基制药(CELG)$ 吹水， 几年以后新基会成为全球第2大生物科技公司。第一还是罗氏。查看全文

万事没商量2017-03-30 04:07

$新基制药(CELG)$ 鸟格的查看全文

万事没商量2017-03-24 02:50

$新基制药(CELG)$ 怎么都没人说话了？？查看全文

$新基制药(CELG)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013792  Size: 69 KB 网页链接

$新基制药(CELG)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013796  Size: 42 KB 网页链接

$新基制药(CELG)$ 15-12B Securities registration termination [Section 12(b)] Accession Number: 0001140361-19-022527  Act: 34  Size: 15 KB 网页链接

$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022225  Act: 33  Size: 20 KB 网页链接

$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022228  Act: 33  Size: 20 KB 网页链接

$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022200  Act: 33  Size: 20 KB 网页链接

$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022201  Act: 33  Size: 39 KB 网页链接

$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022206  Act: 33  Size: 39 KB 网页链接

$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022210  Act: 33  Size: 39 KB 网页链接

$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022217  Act: 33  Size: 39 KB 网页链接